1.
Health Aff (Millwood)
; 41(9): 1231-1237, 2022 09.
Article
in English
| MEDLINE | ID: covidwho-2021989
ABSTRACT
During the COVID-19 pandemic, there was slower growth in the number of new waivers authorizing clinicians to provide buprenorphine treatment for opioid use disorder. However, treatment capacity grew at a stable rate as a result of already authorized clinicians obtaining waivers for larger patient panels. Advanced practice nurses accounted for the largest portion of capacity growth during the pandemic.
Subject(s)
Buprenorphine , COVID-19 Drug Treatment , Opioid-Related Disorders , Buprenorphine/therapeutic use , Humans , Opiate Substitution Treatment , Opioid-Related Disorders/drug therapy , Pandemics
2.
JAMA Netw Open
; 5(5): e225996, 2022 05 02.
Article
in English
| MEDLINE | ID: covidwho-1843822